WuXi AppTec Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ge Li
- Full Time Employees
- 39,414
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 288 Fute Zhong Road Shanghai People's Republic of China 200131
- IPO Date
- Feb 24, 2021
- Website
- wuxiapptec.com
- Similar Companies
- Business
- WuXi AppTec Co., Ltd. (WUXAY) operates as a global contract research, development and manufacturing organization (CRDMO) that provides end-to-end pharmaceutical services from drug discovery to commercial manufacturing for the pharmaceutical, biotech and medical device industries worldwide. Founded in 2000 and headquartered in Shanghai, China, the company delivers integrated solutions across Asia, Europe and North America, including WuXi Biology for target discovery to candidate selection in small molecules, peptides, oligonucleotides and biologics; WuXi Chemistry for small molecule CRDMO encompassing discovery, process development, formulation and custom manufacturing; TIDES CRDMO for oligonucleotides and peptides across the supply chain; and Laboratory Testing for DMPK, safety assessments and bioanalytical support in modalities such as PROTACs, ADCs and emerging therapies; with additional capabilities in preclinical testing services. The company serves nearly 6,000 customers in over 30 countries, focusing on small molecules, biologics and cell and gene therapies to accelerate healthcare innovation. In recent developments, WuXi AppTec agrees to sell its U.S. and U.K. Advanced Therapies cell therapy unit to Altaris, LLC, with the transaction expected to close in the first half of 2025 to sharpen focus on its core CRDMO platform; signs a definitive agreement in October 2025 with Hillhouse Investment Management to divest its China-based clinical research services, including WuXi Clinical CRO and WuXi MedKey SMO, pending regulatory approvals; completes a second RMB1.0 billion A-share repurchase program in August 2025, cancelling all repurchased shares; and raises HK$7.70 billion through a share placement earlier in 2025 to support global expansion amid strong revenue growth, with H1 2025 continuing operations revenue up 24.2% year-over-year.
WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
Short Interest in WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY) Increases By 76.7%
WuXi AppTec Co., Ltd. (WUXAY) Q4 2025 Earnings Call Transcript
WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY) Short Interest Update
WuXi AppTec Co., Ltd. (WUXAY) Presents at 44th Annual J.P.
WuXi AppTec (OTCMKTS:WUXAY) Shares Down 1.4% – What’s Next?
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO Industry
China's Corporate Pivots: Alibaba's Food Delivery Gambit and WuXi AppTec's Geopolitical Hedge
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year
China's Wuxi Apptec to raise over $980 million to boost expansion
WuXi AppTec Co., Ltd. (WUXIF) Q2 2025 Earnings Call Transcript
WuXi AppTec Issues Positive Profit Alert for the First Half of 2025
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
Focus: China pharma projects disrupted by Sino-US tensions
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
WuXi AppTec Co., (WUXIF) Ltd. Q1 2025 Earnings Call Transcript